Roche presented Phase 3 data showing adjuvant Tecentriq (atezolizumab) guided by circulating tumor DNA (ctDNA) prolonged survival in a higher‑risk bladder cancer subset identified by blood testing. That readout complements Roche’s regulatory momentum after the FDA approved its CD20 antibody Gazyva for lupus nephritis. The ctDNA‑guided analysis, presented at ESMO, supports more personalized adjuvant strategies by selecting patients at elevated recurrence risk. Separately, the FDA’s approval of Gazyva for lupus nephritis provides Roche with a new labeled indication in immunology, expanding the antibody’s commercial and clinical footprint. Taken together, the data and approval underscore Roche’s dual push in oncology diagnostics‑driven therapy and immunology, with potential downstream effects on trial design, biomarker reimbursement, and competitive positioning.